5 recruiting, 2 unknown, 1 not yet recruiting, 1 withdrawn. 2 Not applicable, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Recruiting 1, Unknown 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow PSC: new trials by email Literature Review of PSC trials Research Report on PSC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PET/MRI of Primary Sclerosing Cholangitis Radiotracer Injection, Contrast Media, Magnetic Resonance, Imaging - PSC | Not yet recruiting | Massachusetts General Hospital | 10 | 2026-12-10 | 2026-10-14 | |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation Fenofibrate (drug), Blood draw for the laboratory assessment, MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA) - Primary Sclerosing Cholangitis, Liver Transplant, Complications | Phase 2 | Recruiting | Mayo Clinic | 80 | 2025-04-15 | 2026-07-17 |
| Colangioids to Define the Genetic Factors Involved in Atypical Primary Sclerosing Cholangitis Use of assembloids as in vitro models to test new pharmacological approaches - PSC | Not applicable | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 80 | 2024-12-01 | 2026-03-24 |
| A Microdose Trial Investigating Binding of [68Ga]Ga-DOTA-CYS-ATH001 in Healthy Subjects and Different Patient Groups. [68Ga]Ga-DOTA-Cys-ATH001 - MASH, PSC | Early Phase 1 | Unknown | Antaros Medical | 30 | 2024-08-01 | 2024-08-29 |
| Global Prospective, Observational Cohort of Adult Patients With Primary Sclerosing Cholangitis (WIND-PSC Study) PSC | Recruiting | PSC Partners Seeking a Cure | 2000 | 2024-05-06 | 2026-10-13 | |
| Value of MRCP+ And Liver Multiscan in the Management of Dominant Strictures in Primary Sclerosing Cholangitis Liver Multiscan sequences baseline, MRCP+ analysis baseline, Liver Multiscan analysis baseline - PSC, MRI | Not applicable | Unknown | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 50 | 2022-05-01 | 2022-05-04 |
| Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients Primary Sclerosing Cholangitis, PSC | Recruiting | Mayo Clinic | 300 | 2021-03-08 | 2026-02-17 | |
| Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study Quantitative Multi parametric MRI and enhanced MRCP - Primary Sclerosing Cholangitis, PSC | Withdrawn | Perspectum | 2020-12-21 | 2021-07-21 | ||
| Swiss Primary Sclerosing Cholangitis Cohort Study Cholangitis, Sclerosing, PSC | Recruiting | Fondazione Epatocentro Ticino | 120 | 2017-02-28 | 2025-08-19 |
Cholangitis, Sclerosing (4) · Cholangiocarcinoma (1) · Crohn Disease (1) · Fibrosis (1)
Digestive System Diseases (5) · Bile Duct Diseases (4) · Biliary Tract Diseases (4) · Cholangitis (4) · Adenocarcinoma (1) · Carcinoma (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1) · Inflammatory Bowel Diseases (1) · Intestinal Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Blood Specimen Collection (1) · Cholangiopancreatography, Magnetic Resonance (1) · Contrast Media (1) · Diagnostic Imaging (1) · Fenofibrate (1) · Magnetic Resonance Spectroscopy (1) · Pharmaceutical Preparations (1)
Mayo Clinic (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Antaros Medical (1) · Fondazione Epatocentro Ticino (1) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico (1) · Massachusetts General Hospital (1) · PSC Partners Seeking a Cure (1) · Perspectum (1)
United States (4) · Italy (2) · Canada (1) · Germany (1) · New Zealand (1) · Sweden (1) · Switzerland (1) · United Kingdom (1)
Channa Jayasekera (1) · Cynthia Levy, MD (1) · Cyriel Ponsioen, MD PhD (1) · Johan Vessby (1) · Konstantinos Lazaridis, MD (1) · Onofrio Catalano, MD, Ph.D (1) · Stephen Rossi, PharmD (1)
2023 (1), RC2DK118619 (1)